Abbott Laboratories (NYSE:ABT) Stock Sale Revealed by Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on September 17th. The trade occurred in the Representative’s “KEAN FAMILY PARTNERSHIP” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 9/30/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 8/10/2026.

Abbott Laboratories Trading Up 3.8%

NYSE ABT opened at $110.27 on Tuesday. The stock has a market capitalization of $190.80 billion, a P/E ratio of 41.14, a P/E/G ratio of 1.80 and a beta of 0.59. The business has a 50 day simple moving average of $104.23 and a 200 day simple moving average of $101.99. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same period last year, the company earned $1.30 earnings per share. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. Research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 94.03%.

Analysts Set New Price Targets

A number of brokerages have commented on ABT. Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Citigroup reduced their price target on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Argus lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $119.00 to $127.00 in a research report on Friday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $118.32.

Institutional Trading of Abbott Laboratories

Several institutional investors have recently added to or reduced their stakes in the company. CenterBook Partners LP bought a new position in Abbott Laboratories in the third quarter worth approximately $633,000. Asset One Wealth Management LLC increased its stake in shares of Abbott Laboratories by 21.4% during the third quarter. Asset One Wealth Management LLC now owns 4,457 shares of the healthcare product maker’s stock valued at $440,000 after buying an additional 787 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Abbott Laboratories by 6.0% in the third quarter. International Assets Investment Management LLC now owns 14,823 shares of the healthcare product maker’s stock valued at $1,433,000 after acquiring an additional 839 shares in the last quarter. Heritage Family Offices LLP bought a new stake in shares of Abbott Laboratories in the third quarter valued at about $216,000. Finally, Calamos Wealth Management LLC lifted its stake in Abbott Laboratories by 3.4% in the third quarter. Calamos Wealth Management LLC now owns 6,430 shares of the healthcare product maker’s stock worth $635,000 after acquiring an additional 211 shares during the period. Institutional investors own 75.18% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.